Apellis Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Apellis Pharmaceuticals Inc in the first quarter 2026?
Apellis Pharmaceuticals Inc achieved a return on average equity (ROE) of 39.71 % in its first quarter 2026 a new company high.

ROE has advanced compared to 8.2% in the fourth quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 23 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 146, from total ROE ranking in the fourth quarter 2025 at 1260.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	152.67 %	61.96 %	69.18 %	-40.87 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	133	22	45	-228	-224
Return On Equity (TTM)	39.71 %	8.2 %	18.94 %	-116.09 %	-100.06 %
APLS's Total Ranking	# 146	# 1260	# 227	# 2173	# 3212
Equity (TTM) in Millions	415	370	401	156	164
Seq. Equity Change	12.1 %	-7.73 %	156.66 %	-4.82 %	-28.15 %
Seq. Net Income Change	-	-	-	-	-

Back to APLS Management Effectiveness >> APLS's 5 Years Annual ROE >> Compare APLS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 24
Sector	# 48
Overall	# 146

Return On Equity Statistics
High	Average	Low
39.71 %	-446.16 %	-5796.7 %
(Mar 31 2026)		(Dec 31 2021)

APLS Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	370	229	195	170	199
Y / Y Equity Change	61.96 %	17.49 %	14.51 %	-14.49 %	-2.88 %
Net Income in Millions	22	-198	-529	-652	-746
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	6.05 %	-86.58 %	-271.76 %	-383.92 %	-375.69 %

Back to APLS Management Effectiveness >> APLS's 5 Years Annual ROE >> Compare APLS ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 6.05 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
APLS's' Return on Equity at Yahoo Finance
APLS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for APLS's Competitors
Subscribers only: Roe for Apellis Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for APLS's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector	ROE
Eli Lilly And Company	101.17 %
Alnylam Pharmaceuticals Inc	98.29 %
Qhslab Inc	91.63 %
Amgen Inc	89.41 %
Exelixis Inc	88.60 %
Entera Bio Ltd	87.97 %
Tg Therapeutics Inc	87.36 %
Zevra Therapeutics Inc	81.34 %
Earth Science Tech Inc	71.44 %
Idexx Laboratories Inc	70.87 %
Elite Pharmaceuticals Inc	68.60 %
Pulmatrix Inc	66.91 %
Escalon Medical Corp	66.85 %
3m Company	65.54 %
Aurinia Pharmaceuticals Inc	64.48 %
Zoetis Inc	62.41 %
Vaxart Inc	61.43 %
Dariohealth Corp	60.52 %
Nrc Health	57.25 %
Lifemd Inc	56.68 %
Oramed Pharmaceuticals Inc	55.40 %
Innoviva Inc	47.59 %
Concentra Group Holdings Parent Inc	46.95 %
Liquidia Corporation	46.82 %
Tenet Healthcare Corp	44.20 %
Theravance Biopharma inc	43.85 %
Gilead Sciences Inc	42.33 %
Transmedics Group Inc	41.92 %
Abeona Therapeutics Inc	41.40 %
Apellis Pharmaceuticals Inc	39.71 %

Date modified: 2026-08-30T14:57:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.